- Trial Phase
- Phase 3
- Time to Market
- If Phase 3 succeeds, NDA submission mid-2027, potential FDA decision ~late 2027 to mid-2028.
- Why 9/10
- The Phase 3 ENSURE topline readout expected by end of 2026 (~Q4 2026) is a make-or-break binary for a company whose value is almost entirely this one drug. This qualifies for a 9 on the impact scale.
The single most important event for IMUX is the Phase 3 ENSURE topline readout due by year-end 2026 (approximately 3-4 months from now). A positive result triggers NDA submission in mid-2027 and potentially transforms the company; a negative or mixed result would eliminate virtually all pipeline value. The stock is technically oversold (RSI 14 at 30.35, stochastic oversold) and near its Bollinger lower band, while elevated short volume (~45% weighted ratio over 17 sessions) and 7 days to cover create squeeze potential in either direction at the readout.
Price Chart
Executive Summary
Vidofludimus calcium (IMU-838) is Immunic's sole late-stage asset — an oral, next-generation DHODH inhibitor in Phase 3 (ENSURE trials) for relapsing multiple sclerosis. The company raised $200M via a PIPE in early 2026, ending Q2 with $155.1M cash to fund operations into late 2027. Top-line Phase 3 data is expected by year-end 2026, with NDA submission targeted for mid-2027. Analyst consensus is strongly bullish (17 positive ratings vs 1 hold), with a mean price target of $43.09 — implying ~146% upside — though covering firms have below-average track records. Two notable new institutional holders (Millennium Management, Aberdeen Group) appeared in Q2 2026. This is a high-conviction, single-asset binary: success could launch a major new oral MS therapy; failure would leave the company with no late-stage pipeline.
How It Works
An oral tablet that inhibits an enzyme called DHODH, which immune cells need to proliferate. By blocking this enzyme, vidofludimus calcium is designed to reduce the overactive immune attack on nerve-insulating myelin in multiple sclerosis — effectively calming the immune system in a targeted way. It's a next-generation version of the same class as the already-approved MS drug teriflunomide (Aubagio), but designed with improved properties.
Trial Status
Two pivotal Phase 3 ENSURE trials in relapsing multiple sclerosis are ongoing. Top-line data is expected by end of 2026. NDA submission is targeted for mid-2027. The company completed a $200M private placement (PIPE) in early 2026 to fund these trials and preparation for commercialization. Q2 2026 net loss was $34.1M; cash of $155.1M provides runway into late 2027. New CEO Erik Lundgren (ex-Roche/Genentech, led Ocrevus launch) and CMO Michael Panzara (ex-Sanofi/Biogen, multiple MS approvals) were brought on to lead the late-stage and commercialization effort.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 ENSURE topline data readout (by year-end 2026)
- NDA submission (targeted mid-2027)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
IMMUNIC, INC. 8-K IMUX ·Originating report